Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.

FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.

Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.

Michael Lattanzi discusses treatment plans and research in the community.

Hans Hammers discusses trial design and patient selection in the adjuvant setting.

Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries

David McDermott discusses melanoma and renal data. We never get to bladder or lung.

Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer

Silke, Tom and Brian cover the bases.

Neeraj Agarwal addresses the issues raised at the meeting.

Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005

Pedro Barata summarises his ASCO GU discussion on this topic.

Andrea Apolo describes the results of this positive trial.

Kim Chi discussed the prostate cancer oral session at ASCO GU 2024.

Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.

Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.

What to look out for in bladder, prostate and renal cancer at this year's meeting.

Karim Fizazi discusses the clinical and biomarker components of this data.

Thomas Zilli discusses controversies around radiotherapy in prostate cancer.

Silke Gillessen and Betrand Tombal discuss the questions which will address this issue in Lugano in March 2024.

Silke Gillessen discusses this biannual meeting taking place in Lugano in March 2024.

Cristina Suarez discusses the year in review.

Elena Castro, Begoña Valerrama y Cristina Suárez analizan lo más destacado del cáncer en urología en 2023

Tanya Dorff discusses her favourite prostate cancer studies of the year.

Kala Sridhar discusses all the key trials in 2023. She also reveals her favourite Xmas song.